Komori
Cuorips (4894) · InitiativeAdvanced

Securing intellectual property rights and avoiding infringement of third-party rights

First written in FY2023. 3 of 4 entries say "Advanced", first in FY2025. Latest entry: FY2026.

4entries
4years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2025 – FY20262023: 120232024: 020242025: 120252026: 22026
Same theme, other companies
Protecting and Strengthening Core Value through Intellectual Property ManagementA theme 42 companies write about · 0 as a headwind · 42 as a tailwind

12 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 42 companies compared. The sentences above are computed from all 42.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「This facility achieved a significant increase in capacity by using local-control technology based on an original design concept, including multiple clean booths of the same cleanliness grade arranged in parallel. Patents have been obtained in Japan (Patent No. 7609440), the United States (Patent No. 12455083) and Europe (Patent No. 4079376).」

    For CLiC-1’s local-control technology, the company progressed from patents obtained in Japan and Europe and a pending U.S. application to also obtaining a U.S. patent.
  2. 2026-06-10AdvancedEarnings presentation

    「Filed a new patent application based on clinical trial results」

    治験結果を基礎とする新規特許出願が示され、知的財産権確保の取り組みが具体化した。
  3. FY2025AdvancedAnnual report

    「Patents obtained in Japan (Patent No. 7609440) and Europe (Patent No. 4079376); patent application pending in the United States.」

    For CLiC-1’s local-control technology, the company disclosed patents obtained in Japan and Europe and a pending U.S. application, further substantiating its intellectual-property base.
  4. FY2023First statedAnnual report

    「We will manage our intellectual property in close cooperation with our patent attorneys in order to maintain and secure our intellectual property rights and avoid infringing the intellectual property rights of third parties.」

    The company regards its intellectual-property base, including exclusive rights from Osaka University, the license from DAIICHI SANKYO COMPANY,LIMITED., and transferred patents and know-how, as an important issue for business continuity.
Moved together

"Obtained manufacturing and marketing approval for human iPS cell-derived cardiac muscle cell sheets and their commercialization" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333332★123456
  1. ★This thread
  2. 1Obtained manufacturing and marketing approval for human iPS cell-derived cardiac muscle cell sheets and their commercialization3×
  3. 2Approval obtained for a myocardial cell sheet in the United States and Europe, with expansion of sales regions3×
  4. 3Establishment of Manufacturing and Marketing Licensing, Sales and Distribution, and Information-Provision Systems3×
  5. 4Expanding the one-stop CDMO business using CLiC-13×
  6. 5Expansion of the Cell Culture Processing Facility3×
  7. 6Joint development of catheter-based cell transplantation therapy2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Cuorips yet. It last moved in the Earnings presentation of 2026-06-10: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Securing intellectual property rights and avoiding infringement of third-party rights | Cuorips Inc. (4894) | Komori